UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 23, 2021
Inozyme Pharma, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
001-39397 |
|
38-4024528 |
|
321 Summer Street, Suite 400 Boston, Massachusetts |
|
02210 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (857) 330-4340
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading symbol(s) |
|
Name of each exchange on which registered |
|
Common stock, par value $0.0001 per share |
|
INZY |
|
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
At the annual meeting of stockholders of Inozyme Pharma, Inc. (the “Company”) held on June 23, 2021, the Company’s stockholders voted on the following proposals:
|
|
1. |
The following nominees were elected to the Company’s Board of Directors as Class I directors for terms expiring at the 2024 annual meeting of stockholders. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows: |
|
|
|
Votes For |
|
Votes Withheld |
|
Broker Non-Votes |
|
Axel Bolte |
|
16,151,808 |
|
1,066,974 |
|
681,573 |
|
Robert Hopfner |
|
16,194,711 |
|
1,024,071 |
|
681,573 |
|
Edward Mathers |
|
15,168,508 |
|
2,050,274 |
|
681,573 |
|
|
2. |
The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2021 was ratified. The results of the stockholders’ vote with respect to such ratification were as follows: |
|
Votes For: |
|
|
17,899,994 |
|
Votes Against: |
|
|
20 |
|
Votes Abstaining: |
|
|
341 |
|
Broker Non-Votes: |
|
|
— |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
INOZYME PHARMA, INC. |
||
|
|
|
|
|
|
|
Date: June 24, 2021 |
|
By: |
|
/s/ Axel Bolte |
|
|
|
|
|
Name: Axel Bolte |
|
|
|
|
|
Title: President and Chief Executive Officer |